可溶性FKN和IL-18在冠心病患者血清中的表达
|
摘要
背景
冠状动脉粥样硬化性心脏病(CHD,简称冠心病)是最常见的危害人类生命的疾病之一,其发病的炎症反应机制越来越受到人们的重视,炎症反应在不稳定动脉粥样硬化斑块中的发生、发展及破裂中起重要作用,而介导炎症反应的趋化因子则成为研究中的热点。新近发现一种新的趋化因子FKN(fractalkine,又名不规则趋化因子),由炎症内皮细胞释放,在动脉粥样硬化(AS)斑块中过量表达,介导白细胞的粘附、趋化和血管平滑肌细胞(VSMC)的迁移,促进血小板活化,增强自然杀伤细胞(NK)的细胞毒性作用,导致血管内皮损伤,因此FKN被认为是AS的危险因素。炎症反应在冠心病的发病机制中越来越被关注,多种炎症标志物也成为该研究领域的热点,其中IL-18备受重视。IL-18是近来年发现的一个重要的多效能促炎因子,主要由活化的巨噬细胞和枯否氏细胞产生,能诱导T淋巴细胞、B淋巴细胞和自然杀伤细胞生成IFN-γ,另外还能诱导NO、IL-12等促炎因子的产生,在炎症和免疫反应中发挥重要作用。而近期有研究表明,IL-18可能通过调控其他炎症因子或生物活性物质,参与动脉粥样硬化的进展,使斑块变得不稳定,且易破裂继之血栓形成而导致急性冠脉综合症的发生。FKN介导单核细胞向血管内皮下迁移,可能在IL-18的诱导下上调FKN的表达而发挥促炎作用。
目的
探讨不同类型冠心病患者血清中可溶性趋化因子FKN(Fractalkine)和白介素-18(IL-18)的变化及其临床意义。
方法
经冠状动脉造影排除冠心病的对照组21例,稳定性心绞痛(SAP)组32例,急性冠脉综合症(ACS)组30例,用酶联免疫吸附法测定各组血清中sFKN和IL-18的水平,比较各组之间sFKN和IL-18水平差异,同时研究sFKN与IL-18、Gensini积分之间的相关性。
结果
与对照组相比,血清sFKN在SAP组差异无统计学意义(P>0.05),在ACS组显著升高(P<0.01)。与对照组相比,IL-18在SAP组和ACS组显著升高(P<0.01),其中ACS组显著高于SAP组(P<0.01)。Pearson直线相关分析显示：ACS组血清sFKN和IL-18浓度有相关性(r=0.776),sFKN与Gensini积分无相关性。
结论
血清sFKN和儿-18是冠心病发病过程中的重要炎症介质。
Background
Coronary heart disease(CHD)is the most common form of the disease that harmful to hunman life.The inflammation response mechanism is paid more attention. Vascular inflammatory reaction plays an imporant role in the occurrence, development and rupture of unstable atherosclerotic plaque. Chemokine becomes the hot point for inducing inflammatory reaction. The newly discovered that chemotactic factor FKN (fractalkine, the irregular chemokine), which released by inflammatory endothelial cells,is excessive expressin in atherosclerosis (AS) plaques,and it can mediated the adhesion、chemotaxis of white cells, and the migration of vascular smooth muscle cells (VSMC),and it can promote platelet activate, enhance the natural killer cells (NK) cytotoxicity, causing vascular endothelial injury,therefore FKN is considered as risk factor of AS. Inflammation in the pathogenesis of coronary heart disease in more and more to be concerned, a variety of inflammatory markers also become the hot research.Among them IL-18 is paid more attention. IL-18 is one of the important discovery in recently that promotes inflammation more efficiency,mainly produced by activated macrophages and kupffer's cells, can induce T lymphocytes, B lymphocytes and natural killer cells generating IFN-Y, also can induce NO, IL - 12 promoting inflammation factors,IL-18 plays an imporant role in immune response in inflammation.Recent studies show that IL-18 participates in progression of atherosclerosis through regulation other inflammatory factor or biological active substance,make plaques become unstable, plaques rupture followed by thrombosis,and lead to acute coronary syndrome. FKN can mediated mononuclear cells migrate to vascular endothelium, playing an important role in promoting inflammation,maybe under the induction of IL-18.
Objection
The aim of my study was to investigate the changes of soluble fractalkine (sFKN) and interleukin-18(IL-18) in patients with coronary heart disease and explore the clinical significance
Methods
There were 62 patients with coronary heart disease enrolled, including 32 cases with stable angina pectoris(SAP),30 cases with acute coronary syndrome(ACS),and 21 normal controls,measured the serum level of sFKN and IL-18 by enzyme linked immunosorbent assay, then compare the serum level of sFKN and Gensini score among groups.
Results
The serum levels of sFKN was significantly increased in ACS group (P<0.01), however there was no significant differences between control group and stable angina group. The serum levels of IL-18 in SAP and ACS groups were significantly higher than those in normal controls (P<0.01),and that in ACS group was significantly higher than those in SAP group (P<0.01).Liner regression showed in ACS group,sFKN was related to IL-18 (r=0.776).But compared sFKN with Gensini score, there was no significant correlation.
Conclusion
These findings suggest that sFKN and IL-18 play an important role in development of coronary heart disease.
冠状动脉粥样硬化性心脏病(CHD,简称冠心病)是最常见的危害人类生命的疾病之一,其发病的炎症反应机制越来越受到人们的重视,炎症反应在不稳定动脉粥样硬化斑块中的发生、发展及破裂中起重要作用,而介导炎症反应的趋化因子则成为研究中的热点。新近发现一种新的趋化因子FKN(fractalkine,又名不规则趋化因子),由炎症内皮细胞释放,在动脉粥样硬化(AS)斑块中过量表达,介导白细胞的粘附、趋化和血管平滑肌细胞(VSMC)的迁移,促进血小板活化,增强自然杀伤细胞(NK)的细胞毒性作用,导致血管内皮损伤,因此FKN被认为是AS的危险因素。炎症反应在冠心病的发病机制中越来越被关注,多种炎症标志物也成为该研究领域的热点,其中IL-18备受重视。IL-18是近来年发现的一个重要的多效能促炎因子,主要由活化的巨噬细胞和枯否氏细胞产生,能诱导T淋巴细胞、B淋巴细胞和自然杀伤细胞生成IFN-γ,另外还能诱导NO、IL-12等促炎因子的产生,在炎症和免疫反应中发挥重要作用。而近期有研究表明,IL-18可能通过调控其他炎症因子或生物活性物质,参与动脉粥样硬化的进展,使斑块变得不稳定,且易破裂继之血栓形成而导致急性冠脉综合症的发生。FKN介导单核细胞向血管内皮下迁移,可能在IL-18的诱导下上调FKN的表达而发挥促炎作用。
目的
探讨不同类型冠心病患者血清中可溶性趋化因子FKN(Fractalkine)和白介素-18(IL-18)的变化及其临床意义。
方法
经冠状动脉造影排除冠心病的对照组21例,稳定性心绞痛(SAP)组32例,急性冠脉综合症(ACS)组30例,用酶联免疫吸附法测定各组血清中sFKN和IL-18的水平,比较各组之间sFKN和IL-18水平差异,同时研究sFKN与IL-18、Gensini积分之间的相关性。
结果
与对照组相比,血清sFKN在SAP组差异无统计学意义(P>0.05),在ACS组显著升高(P<0.01)。与对照组相比,IL-18在SAP组和ACS组显著升高(P<0.01),其中ACS组显著高于SAP组(P<0.01)。Pearson直线相关分析显示：ACS组血清sFKN和IL-18浓度有相关性(r=0.776),sFKN与Gensini积分无相关性。
结论
血清sFKN和儿-18是冠心病发病过程中的重要炎症介质。
Background
Coronary heart disease(CHD)is the most common form of the disease that harmful to hunman life.The inflammation response mechanism is paid more attention. Vascular inflammatory reaction plays an imporant role in the occurrence, development and rupture of unstable atherosclerotic plaque. Chemokine becomes the hot point for inducing inflammatory reaction. The newly discovered that chemotactic factor FKN (fractalkine, the irregular chemokine), which released by inflammatory endothelial cells,is excessive expressin in atherosclerosis (AS) plaques,and it can mediated the adhesion、chemotaxis of white cells, and the migration of vascular smooth muscle cells (VSMC),and it can promote platelet activate, enhance the natural killer cells (NK) cytotoxicity, causing vascular endothelial injury,therefore FKN is considered as risk factor of AS. Inflammation in the pathogenesis of coronary heart disease in more and more to be concerned, a variety of inflammatory markers also become the hot research.Among them IL-18 is paid more attention. IL-18 is one of the important discovery in recently that promotes inflammation more efficiency,mainly produced by activated macrophages and kupffer's cells, can induce T lymphocytes, B lymphocytes and natural killer cells generating IFN-Y, also can induce NO, IL - 12 promoting inflammation factors,IL-18 plays an imporant role in immune response in inflammation.Recent studies show that IL-18 participates in progression of atherosclerosis through regulation other inflammatory factor or biological active substance,make plaques become unstable, plaques rupture followed by thrombosis,and lead to acute coronary syndrome. FKN can mediated mononuclear cells migrate to vascular endothelium, playing an important role in promoting inflammation,maybe under the induction of IL-18.
Objection
The aim of my study was to investigate the changes of soluble fractalkine (sFKN) and interleukin-18(IL-18) in patients with coronary heart disease and explore the clinical significance
Methods
There were 62 patients with coronary heart disease enrolled, including 32 cases with stable angina pectoris(SAP),30 cases with acute coronary syndrome(ACS),and 21 normal controls,measured the serum level of sFKN and IL-18 by enzyme linked immunosorbent assay, then compare the serum level of sFKN and Gensini score among groups.
Results
The serum levels of sFKN was significantly increased in ACS group (P<0.01), however there was no significant differences between control group and stable angina group. The serum levels of IL-18 in SAP and ACS groups were significantly higher than those in normal controls (P<0.01),and that in ACS group was significantly higher than those in SAP group (P<0.01).Liner regression showed in ACS group,sFKN was related to IL-18 (r=0.776).But compared sFKN with Gensini score, there was no significant correlation.
Conclusion
These findings suggest that sFKN and IL-18 play an important role in development of coronary heart disease.
引文
[1]. Ross R. Atherosclerosis is an inflammatory disease. Am Heart [J].1999;138(5 Pt 2):S419-S420.
[2]. Laing KJ, Secombes CJ. Chemokines. Dev Comp Immunol.2004;28(5):443-460.
[3]. Murdoch C, Finn A. Chemokine receptors and their role in inflammation and infectious diseases. Blood.2000;95(10):3032-3043.
[4]. Wagsater D, Olofsson PS, Norgren L, et al. The chemokine and scavenger receptor CXCL16/SR-PSOX is expressed in human vascular smooth muscle cells and is induced by interferon gamma. Biochem Biophys Res Commun.2004; 325(4):1187-1193.
[5]. Zhuge X, Murayama T, Arai H, et al. CXCL16 is a novel angiogenic factor for human umbilical vein endothelial cells. Biochem Biophys Res Commun.2005;331(4):1295-1300.
[6]. Lundberg GA, Kellin A, Samnegard A, et al. Severity of coronary artery stenosis is associated with a polymorphism in the CXCL16/SR-PSOX gene. [J] Intern Med.2005; 257(5):415-422.
[7]. Cockwell P, Chakravorty SJ, Girdlestone J,et al.Fractalkine expression in human renal inflammation.[J].Pathol.2002;196(1):85-90.
[8]. Furuiehi K, Wada T. lwata Y, Sakai N, Yoshimoto K, Shimizu M, et al.Up-regulation of fractalkine in human crescentic glomerulonephritis. Nephron.2001;87(4):314-320.
[9], Zhang XJ, Wei HM, Chen QF, et al, Activation of human natural killer cells bv recombinant membrane-expressed fraetalkine on the surface of tumor cells.Oncology Reports.2007;17(6):1371-1375.
[10]. Bazan JF,Bacon KB,Hardiman G, et al. A new class of membrance-bound chemokine with a CX3C motif[J].Nature,1997,385:640.
[11]. Mc Dermott DH, Halcox JP, Schenke WH, et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis.2001,89(5):401
[12]. Greaves DR,Hakkinen T,Lucas AD et al. Linked chromosome 16q13 chemokines, macrophage derived chemokine, ractalkine,and thymus and activation regulated chemokine,are expressed in human atherosclerotic lesions[J].Arterioscler Thromb Vasc Biol,2001,21(6):923
[13]. Hulthe J, McPheat W, Samnegard A, et al. Plasma interleukin(IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C reactive Protein and IL—6[J].Atherosclerosis,2006, 188(2):450
[14]. Mallat Z, Corbaz A, Scoazec A, et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability[J].Circulation,2001,104(14):1598
[15]. Gensini GGA more meaningful scoring system for determining the severity of coronary heart disease.Am J Cardiol,1983,51:606-607.
[16]. Ross R,Atherosclerosis is an inflammatory disease.Am Heart [J].1999,138 (5pt2):S 419-420.
[17]. Me Dermott DH, Halcox JP, Schenke WH, et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis.2001,89(5):401
[18]. Greaves DR,Hakkinen T,Lucas AD et al. Linked chromosome 16q13 chemokines, macrophage derived chemokine, ractalkine,and thymus and activation regulated chemokine,are expressed in human atherosclerotic lesions[J].ArteriosclerThromb Vase Biol,2001,21(6):923
[19]..Bazan JF,Bacon KB,Hardiman G,et al. A new class of membrance-bound chemokine with a CX3C motif.Nature.1997;385:640-644.
[20]. Schafer A,Schulz C,Eiqenthaler M,et al.Novel role of the membrance bound chemokine fractalkine in platelet activation and adhesion.Blood.2004 Jan 15;103(2):407-412
[21]. Goda S, lmai T, Yoshie O, et al.CX3C — chemokine, fractalkine-enhanced adhesion of THP — 1 cells to endothelial cells through integrin-dependent and independent mechanism.[J] Immunol.2000 Apr 15; 164(8):4313—4320.
[22]. Yoneda O,Imai T,Gouda S,et al.NK cell-mediated vascularinjury.[J] Immunol.2000; 164:4055-4621.
[23]. Yoneda O,Imai T,Inoue H,et al.Membrane bound form of FKN induces IFN-r production by NK cells:a role for Th1 response.Eur[J] Immunol.2003;33:53-581.
[24]. Combadiere C, Potteaux S, Gao JL,et al.DeCreased atheros Clerotic lesion Fonnation in CXCR1/apolipoprotein E double knockout mice. Circulation.2003;17:1009-1016
[25]. Nishimura M,Umehara H,Nakayama T,et al.Dual functions of Fkn/CX3CR1 intrafficking of circulating cytotoxic effector lymphocytes that are defined by CX3CR1 expression.[J] Immunol.2002;138:6173-61801.
[26]. Kawasaki D,Tsujino T,Morimoto S,et al.Plasma interleukin-18 concentration:a novel marker of myocardial ischemia rather than necrosis in humans.Coron Artery DIS.2005,16(7):437-441.
[1]. Ross.R.Atherosclerosis is an inflammatory disease. Am heart [J].1999,138 (5pt2) S419-420.
[2]. Zlotnik A,Yoshie O .Chemokines:a new classification system anf their role in immunity.2000,12(2):121-127.
[3]. Bazan JF,Bacon KB,Hardiman G,et al. A new class of membrance-bound chemoki-ne with a CX3C motif.Nature.1997;385:640-644.
[4]. Nomiyama H, Imai T, Kusuda J, et al. Human chemokines fractalkine(SCYDI), MDC(SCYA22)and TARC(Sc1fA17)are clustered on chromosome 16q13.Cytogenet Cell Genet.1998;81(1):10-11.
[5]. Garton KJ, Gough PJ, Blobel CP, MurpHy G, Greaves DR, Dempsey PJ, et al.Tumor necrosis factor-alpha-converting enzyme(ADM17) mediates the cleavage and shedding of fractalkine(CX3CLI). Biol Chem.2001;276(4):37993-38001.
[6]. Nishiyori A,Minami M,Ohtani Y,et al.Localization of fractalkine and CXC3CR1 mRNAs in rat brain:dose fractalkine play a role in signaling from neuron to microgila? FEBS Lett.1998 Jun 12;429(2):167-172
[7]. Harrison JK, Jiang Y, Chen S, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia.Proc Natl Acad Sci USA.1998;95:10896-10901.
[8]. Greaves DR,Hakkinen T, Lucas AD, et al. Linked chromosome 16q 13 chemokines, macrophage-derived chemokine. fractalkine, and thymusand activation-regulated chemokine are expressed in human atherosclerotic lesions.Arterioscler Thromb Vasc BiOl.2001;21:923-929.
[9]. Foussat A, Coulomb-L'Hermine A, Gosling J, Krzysiek R, Durand-Gasselin I, Schall T, et al. Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production offractalkine in human.Eur J Immunol.2000;30(1):87-97.
[10]. Kanazawa N, Nakamura T, Tashiro K, Muramatsu M, Morita K, Yoneda K,et al.Fractalkine and macrophage-derived chemokine:T cell-attracting chemokinesexpressed in T cell area dendritic cells.Eur J lmmunol.1999;29(6):1925-1932.
[11]. Papadopoulos EJ, Sassetti C, Saeki H, Yamada N, Kawamura T, FitzhughDJ, et al. Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is upregulated upon dendritic cell maturation.Eur J Immuno,1999;29(8):2551-2559.
[12]. Ludwig A, Berkhout T, Moores K, Groot P, Chapman G. Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. Immanol.2002;168(2):604-612.
[13]. Lucas AD, Chadwick N, Warren BF, Jewell DP, Gordon S, Powrie F, et al. The transmembrane form of the CX3CL1 chemokine fractalkine is expressed predominantly by epithelial cells in vivo. Am J Pathol 2001;158(3):855-866.
[14]. Umehara H,Bollm ET,Okazaki T,et al.Fractalkine and vascular injury.Trends Immunol.2001;22:602-607.
[15]. Fujimoto K, lmaizumi T. Yoshida H, et al. Interferon—gamma stimu-lates fractalkine expression in human bronchial epithelial cells and regulates mononuclear cell adherence J Am J Respir Cell Mol Biol.2001,25(2):233-238.
[16]. Umehara H, Goda S, Imai T, Nagano Y, Minami Y. Tanaka Y, Okazaki T, Bloom ET, Domae N. Fractalkine, a CX3C-chemokine, functions predominantly as an adhesion molecule in monocytic eell line THP-1. Immanol Cell Binl.2001; 79(3):298-302.
[17]. Haskell CA, Cleary MD, Charo IF. Unique role of the chemokine domain of fractalkine in cell capture. Kinetics of receptor dissociation correlate with cell adhesion. J Biol Chem. 2000:275(44):34183-34189.
[18].18.M.Fong,A.Robinson,A.Steeber et al.Fractalkine and CX3CR1 Mediate a Novel Mechanism of Leukocyte Capture,Firm Adhesion,and Activation under Physiologic Flow.Biol Chem.2002; 277:19418-19423.
[19]. Cook DN, Chen SC, Sullivan LM. Manfra DJ, Wiekowski MT, Prosser DM, et al. Generation and analysis of mice lacking the chemokine fractalkine. Mol Cell Biol.2001;21(9):3159—3165.
[20]. Kerfoot SM, Lord SE, Bell RB, Gill V, Robbins SM, Kubes P. Human fractalkine mediates leukocyte adhesion but not capture under physiological shear conditions; a mechanism for selective monocyte recruitment. Eur J Immunol.2003; 33(3):729-739.
[21]. Combadiere C,Salzwedel K,Smith ED,etal.Identification of CX3CR1.A chemotactic receptor for the human CX3Cchemokine FKN and a fusion coreceptor for HIV-1[J], Biol Chem,1998;273(37):23799-23804.
[22]. Baggiolini M,Dewald B,Moser B.Human chemokines:Anupdate.Annu Rev Immunol.1997; 15:675-705.
[23]. Baggiolini M,Dewald B,Moser B.Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines.Adv Immunol.1994;55:97-179.
[24]. Nishiyori A,Minami M,Ohtani Y,et al.Localization of FKN and CX3-CR1 mRNAs in rat brain:doesFKN play a role in signaling from neuron to microglia.FEBS Lett.1998;429(2):167-172.
[25]. Mizoue LS,Bazan JF,Johnson EC,et al.Solution structure and dynamics of the CX3C chemokine domian of fractalkine and its interaction with an N-terminal fragment of CX3CR1.[J]. Biochemistry,1999,38(5):1402-1410.
[26]. Jung S. Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, et al, Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion andgreen fluorescent protein reporter gene insertion.Mol Cell Biol.2000; 20(11):4106—4114.
[27]. Nishimura M, Umehara E Nakayama T, et al. Dual funaioas of fractalkine/CX3CRⅠ in trafficking of circulating cytomxie effector lymphocytcs that are defined by CX3CR1 expression. [J] Immunol.2002;138:6173-6180.
[28]. Frafieelli P, Sironi M, Bianchi Get al. Fmetalkine(CX3CLI)as an amplification circuit of polarized Thl responses. [J] Clin Invest.2001;107:1173-1181.
[29]. Haskell CA, Hancock WW, Salant DJ, Gao W, Csizmadia V, Peters W, et al. Targeted deletion of CX(3)CRI reveals a role for fractalkine in cardiac allograft rejection. [J] Clin Invest.2001; 108(5):679-688。
[30]. Faure S,Meyer L,Costagliola D,et al.Rapid progression to ADIS among HIV-1 individuals with an allelic variant of CX3CR1 chemokine receptor. [J].science,2000,287:2274-2277.
[31]. Umehara H,Goda S,Imai T,et al.FKN.a CX3C-chemokine functions predominantlyas an adhesion molecule in monocytic cell line THP-1.Immunol Cell Biol.2001,79:298-3021.
[32]. Umehara H, Bollm ET, Okazaki T,et al.Fractalkine and vascular injury. [J] Trends Immunol,2001,22:602-607.
[33]. Kerfoot SM, Lord SE,Bell RB,et al.Human fractalkine mediates leukocyte adhesion but not capture under physiological shear conditions:a mechanism for selective monocyte recruitment.[J] Eur J Immunol,2003,33:729-739
[34].34 Ancuta P,Rao R,Moses A,et all Fkn preferentially mediates arrest and migration of CD 16+monocytes. [J] Exp Med.2003; 197:1701-17071.
[35]. Foussat A, Coulomb-L'Hermine A, Gosling J, Krzysiek R, Durand-Gasselin I, Schall T, et al. Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production offractalkine in human. Eur J Immunol.2000; 30(1):87-97.
[36]. Harcourt J,Alvarez R,Jones LP,et al.Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1 T+cell respones. [J].Immunol.2006,176:1600-1608
[37]. Yoneda O,Imai T,Gouda S,et al.NK cell-mediated vascularinjury.[J].Immunol 2000; 164:4055-4621.
[38]. Yoneda O,Imai T,Inoue H,et al.Membrane bound form of FKN induces IFN-r production by NK cells:a role for Thl response.Eur J Immunol.2003;33:53-581.
[39]. Nishimura M,Umehara H,Nakayama T,et al.Dual functions of Fkn/CX3CR1 intrafficking of circulating cytotoxic effector lymphocytes that are defined by CX3CR1 expression.[J] Immunol.2002;138:6173-61801.
[40]. Ross R,Atherosclerosis is an inflammatory disease.Am Heart [J].1999,138 (5pt2): S419-420.
[41]. Poole JC,Florey HW.Changes in the endothelium of the aorta and the behavior Of macrophages in experimental atheroma of rabbits.[J]Pathol Bacteriol.1958;75:245-251.
[42]. Steinberg D.Atherogenesis in PersPeetive:hypercholesterolemia and inflamm-ation as Partuers in crime.NatMed.2002;8:1211-1217.
[43]. Sheikine Y,Hansson G.Chemokines and atheroselerosis.Ann Med.2004;36:98-118.
[44]. Yla Herttuala S,Lipton BA.Rosenfeld ME,et al.Expression of monoeyte chemo-attractant protein-1 in macrophage-rich areas of human and rabbit atherosclerotic lesions,Proc Natl Acid USA.1991;88:5252-5256.
[45]. Yu X,Dluz S,Graves DT,et al.Elevated expression of monocyte chemo-attractant Proteinl by vascular smooth muscle cells in hypercholesterolemic Primates.Proc Natl Acid Sci USA.1992;89:6953-6957.
[46]. Reape TJ,Rayner k,Manning CD,et al.Expression and cellular localization of the CC ehemokines PARC and ELC in human atheroselerotic Plaques.Am J Pathol.1999; 154:365-74.
[47]. Greaves DR,Hakkinen T,Lucas AD,et al.Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, thymus and activation-regulated chemokine are expressed in human atherosclerotic lesions.Arterioscler Thromb Vasc Biol.2002;21:923-929.
[48]. Haque N, Zhang X, French D, et al.CC ehemokine 1-309 is the Principal mono-Cyte chemoattractant induced by apolipoprotein in huaman vacular endothelial cell. [J] Circulation.2000;102:786-792.
[49]. Pattison JM, Nelson PJ, Huie P, et al.Rantes chemokine expression in transpla-Lant-associated aceelerated atherosclerosis.J Heart Lung Transplant.1966;15:1194-1199.
[50]. GuPta SK,et al.J Biol Chem.1998;273:4282-4287.
[51]. Hayes IM,et al.Arterioseler Thromb Vasc Biol.1998:18:397-403.
[52]. Combadiere C, Potteaux S, Gao JL, et al.DeCreased atherosClerotic lesionFonnation in CXCRI/apolipoprotein E double knockout mice. [J]Circulation.2003; 107:1009-1016.
[53]. Mallat Z, Corbaz A, Scoazec A,et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. [J] Circulation,2001,104:1598-1603
[54]. Blankenberg S,Luc G,Ducimetiere P,et al.Interleukin-18 and the risk of coronary heart disease in European men: the prospective epidemiological study of myocardial Infarction (PRIME).[J] Circulation,2003,108(9):2453
[55]. Matsubara T, Ono T, Yamanoi A, et al. Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma[.J] SUR ONC.2007;95(3):241-249.
[56]. L Tang, et al. Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress efectively mouse hepatocellular carcinoma. Gone Ther.2007,14(4):1226-1234
[57]. Zhang XJ, Wei HM, Chen QF, et al, Activation of human natural killer cells bv recombinant membrane-expressed fraetalkine on the surface of tumor cells.Oncology Reports.2007;17(6):1371-1375.
[58]. Ohta M, Tanaka F, Yamaguchi H, et al. lfhe high expression of fraetalkine results in a better prognosis for colorectal cancer patients. Int J Oncol.2005;6(21):41-47
[59]. Robinson LA,Nataraj C, Thomas DW,et al. A role for fractalkine and its receptor (CX3CR1) in cardiac allograf rejection. [J] Immunol.2000;165:6067-6072.
[60]. Pictrzyk MC, Banas B, Wolf K, et al. Quantitative gene expression analysis of fractalkine using laser microdisseetion in biopsies from kidney allografis with acute rejection. Transplant Proc.2004; 36(9):2659-2661.
[61]. Cao G,Lu Y, Gao R, et a 1.Expression of fractalkine, CX3CRI, and vascular endothelial growth factor in human chronic renal allograft rejection. Transplant Proe.2006; 38(7): 1998-2000.
[62]. Hskell C, Hancock WW,Salant DJ, et al. Targeted deletion ofCX3CRI reveals a role for fractalkine in cardiac allograf rejection. [J] Clinlnvest.2001;108:679-688.
[63]. Feng L, Chen S, Gareia GE, et al. Prevention of ciescentie glomemlonephritis by irrmanoneutralization of the fractalkine receptor CX3CR1 rapid communication. Kidney Int.1999;56(2):612-620.
[64]. Cockwell P, Chakravorty SJ, Girdlestone J,et al.Fractalkine expression in human renal inflammation.[J] Pathol.2002;196(1):85-90.
[65]. Combadiere B, Faure S, Autran B, et al. The chemokine receptor CX3CR1 controls homing and anti-viral potencies of CD8 effeetor-mcmory T lymphoeytes in HW-infeeted patients.AIDS.2003;17(9):1279-1290.
[66]. Foussat A, Bouchet-Delbos L, Berrebi D, et al. Deregulation ofthe expression of the fraetalkine/flacctalkine receptor complex in HIV-1·infected patients. Blood.2001;98(6): 1678-1686.
[67]. Faure S,Meyer L,Costagliola D,et al.Rapid progression to AIDS in HIV+individuals with a structural variant of the chemokine receptor CX3CR1.[J] Science,2000,287:2274-2277.
[68]. Marasini B,Cossutta R,Selmi C,et al.Polymorphism of fractalkine receptor CX3CR1 and systemic sclerosis-associated pulmonary arterial hypertension.Clin Dev Immunol,2005, 12:275-279.
[2]. Laing KJ, Secombes CJ. Chemokines. Dev Comp Immunol.2004;28(5):443-460.
[3]. Murdoch C, Finn A. Chemokine receptors and their role in inflammation and infectious diseases. Blood.2000;95(10):3032-3043.
[4]. Wagsater D, Olofsson PS, Norgren L, et al. The chemokine and scavenger receptor CXCL16/SR-PSOX is expressed in human vascular smooth muscle cells and is induced by interferon gamma. Biochem Biophys Res Commun.2004; 325(4):1187-1193.
[5]. Zhuge X, Murayama T, Arai H, et al. CXCL16 is a novel angiogenic factor for human umbilical vein endothelial cells. Biochem Biophys Res Commun.2005;331(4):1295-1300.
[6]. Lundberg GA, Kellin A, Samnegard A, et al. Severity of coronary artery stenosis is associated with a polymorphism in the CXCL16/SR-PSOX gene. [J] Intern Med.2005; 257(5):415-422.
[7]. Cockwell P, Chakravorty SJ, Girdlestone J,et al.Fractalkine expression in human renal inflammation.[J].Pathol.2002;196(1):85-90.
[8]. Furuiehi K, Wada T. lwata Y, Sakai N, Yoshimoto K, Shimizu M, et al.Up-regulation of fractalkine in human crescentic glomerulonephritis. Nephron.2001;87(4):314-320.
[9], Zhang XJ, Wei HM, Chen QF, et al, Activation of human natural killer cells bv recombinant membrane-expressed fraetalkine on the surface of tumor cells.Oncology Reports.2007;17(6):1371-1375.
[10]. Bazan JF,Bacon KB,Hardiman G, et al. A new class of membrance-bound chemokine with a CX3C motif[J].Nature,1997,385:640.
[11]. Mc Dermott DH, Halcox JP, Schenke WH, et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis.2001,89(5):401
[12]. Greaves DR,Hakkinen T,Lucas AD et al. Linked chromosome 16q13 chemokines, macrophage derived chemokine, ractalkine,and thymus and activation regulated chemokine,are expressed in human atherosclerotic lesions[J].Arterioscler Thromb Vasc Biol,2001,21(6):923
[13]. Hulthe J, McPheat W, Samnegard A, et al. Plasma interleukin(IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C reactive Protein and IL—6[J].Atherosclerosis,2006, 188(2):450
[14]. Mallat Z, Corbaz A, Scoazec A, et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability[J].Circulation,2001,104(14):1598
[15]. Gensini GGA more meaningful scoring system for determining the severity of coronary heart disease.Am J Cardiol,1983,51:606-607.
[16]. Ross R,Atherosclerosis is an inflammatory disease.Am Heart [J].1999,138 (5pt2):S 419-420.
[17]. Me Dermott DH, Halcox JP, Schenke WH, et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis.2001,89(5):401
[18]. Greaves DR,Hakkinen T,Lucas AD et al. Linked chromosome 16q13 chemokines, macrophage derived chemokine, ractalkine,and thymus and activation regulated chemokine,are expressed in human atherosclerotic lesions[J].ArteriosclerThromb Vase Biol,2001,21(6):923
[19]..Bazan JF,Bacon KB,Hardiman G,et al. A new class of membrance-bound chemokine with a CX3C motif.Nature.1997;385:640-644.
[20]. Schafer A,Schulz C,Eiqenthaler M,et al.Novel role of the membrance bound chemokine fractalkine in platelet activation and adhesion.Blood.2004 Jan 15;103(2):407-412
[21]. Goda S, lmai T, Yoshie O, et al.CX3C — chemokine, fractalkine-enhanced adhesion of THP — 1 cells to endothelial cells through integrin-dependent and independent mechanism.[J] Immunol.2000 Apr 15; 164(8):4313—4320.
[22]. Yoneda O,Imai T,Gouda S,et al.NK cell-mediated vascularinjury.[J] Immunol.2000; 164:4055-4621.
[23]. Yoneda O,Imai T,Inoue H,et al.Membrane bound form of FKN induces IFN-r production by NK cells:a role for Th1 response.Eur[J] Immunol.2003;33:53-581.
[24]. Combadiere C, Potteaux S, Gao JL,et al.DeCreased atheros Clerotic lesion Fonnation in CXCR1/apolipoprotein E double knockout mice. Circulation.2003;17:1009-1016
[25]. Nishimura M,Umehara H,Nakayama T,et al.Dual functions of Fkn/CX3CR1 intrafficking of circulating cytotoxic effector lymphocytes that are defined by CX3CR1 expression.[J] Immunol.2002;138:6173-61801.
[26]. Kawasaki D,Tsujino T,Morimoto S,et al.Plasma interleukin-18 concentration:a novel marker of myocardial ischemia rather than necrosis in humans.Coron Artery DIS.2005,16(7):437-441.
[1]. Ross.R.Atherosclerosis is an inflammatory disease. Am heart [J].1999,138 (5pt2) S419-420.
[2]. Zlotnik A,Yoshie O .Chemokines:a new classification system anf their role in immunity.2000,12(2):121-127.
[3]. Bazan JF,Bacon KB,Hardiman G,et al. A new class of membrance-bound chemoki-ne with a CX3C motif.Nature.1997;385:640-644.
[4]. Nomiyama H, Imai T, Kusuda J, et al. Human chemokines fractalkine(SCYDI), MDC(SCYA22)and TARC(Sc1fA17)are clustered on chromosome 16q13.Cytogenet Cell Genet.1998;81(1):10-11.
[5]. Garton KJ, Gough PJ, Blobel CP, MurpHy G, Greaves DR, Dempsey PJ, et al.Tumor necrosis factor-alpha-converting enzyme(ADM17) mediates the cleavage and shedding of fractalkine(CX3CLI). Biol Chem.2001;276(4):37993-38001.
[6]. Nishiyori A,Minami M,Ohtani Y,et al.Localization of fractalkine and CXC3CR1 mRNAs in rat brain:dose fractalkine play a role in signaling from neuron to microgila? FEBS Lett.1998 Jun 12;429(2):167-172
[7]. Harrison JK, Jiang Y, Chen S, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia.Proc Natl Acad Sci USA.1998;95:10896-10901.
[8]. Greaves DR,Hakkinen T, Lucas AD, et al. Linked chromosome 16q 13 chemokines, macrophage-derived chemokine. fractalkine, and thymusand activation-regulated chemokine are expressed in human atherosclerotic lesions.Arterioscler Thromb Vasc BiOl.2001;21:923-929.
[9]. Foussat A, Coulomb-L'Hermine A, Gosling J, Krzysiek R, Durand-Gasselin I, Schall T, et al. Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production offractalkine in human.Eur J Immunol.2000;30(1):87-97.
[10]. Kanazawa N, Nakamura T, Tashiro K, Muramatsu M, Morita K, Yoneda K,et al.Fractalkine and macrophage-derived chemokine:T cell-attracting chemokinesexpressed in T cell area dendritic cells.Eur J lmmunol.1999;29(6):1925-1932.
[11]. Papadopoulos EJ, Sassetti C, Saeki H, Yamada N, Kawamura T, FitzhughDJ, et al. Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is upregulated upon dendritic cell maturation.Eur J Immuno,1999;29(8):2551-2559.
[12]. Ludwig A, Berkhout T, Moores K, Groot P, Chapman G. Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. Immanol.2002;168(2):604-612.
[13]. Lucas AD, Chadwick N, Warren BF, Jewell DP, Gordon S, Powrie F, et al. The transmembrane form of the CX3CL1 chemokine fractalkine is expressed predominantly by epithelial cells in vivo. Am J Pathol 2001;158(3):855-866.
[14]. Umehara H,Bollm ET,Okazaki T,et al.Fractalkine and vascular injury.Trends Immunol.2001;22:602-607.
[15]. Fujimoto K, lmaizumi T. Yoshida H, et al. Interferon—gamma stimu-lates fractalkine expression in human bronchial epithelial cells and regulates mononuclear cell adherence J Am J Respir Cell Mol Biol.2001,25(2):233-238.
[16]. Umehara H, Goda S, Imai T, Nagano Y, Minami Y. Tanaka Y, Okazaki T, Bloom ET, Domae N. Fractalkine, a CX3C-chemokine, functions predominantly as an adhesion molecule in monocytic eell line THP-1. Immanol Cell Binl.2001; 79(3):298-302.
[17]. Haskell CA, Cleary MD, Charo IF. Unique role of the chemokine domain of fractalkine in cell capture. Kinetics of receptor dissociation correlate with cell adhesion. J Biol Chem. 2000:275(44):34183-34189.
[18].18.M.Fong,A.Robinson,A.Steeber et al.Fractalkine and CX3CR1 Mediate a Novel Mechanism of Leukocyte Capture,Firm Adhesion,and Activation under Physiologic Flow.Biol Chem.2002; 277:19418-19423.
[19]. Cook DN, Chen SC, Sullivan LM. Manfra DJ, Wiekowski MT, Prosser DM, et al. Generation and analysis of mice lacking the chemokine fractalkine. Mol Cell Biol.2001;21(9):3159—3165.
[20]. Kerfoot SM, Lord SE, Bell RB, Gill V, Robbins SM, Kubes P. Human fractalkine mediates leukocyte adhesion but not capture under physiological shear conditions; a mechanism for selective monocyte recruitment. Eur J Immunol.2003; 33(3):729-739.
[21]. Combadiere C,Salzwedel K,Smith ED,etal.Identification of CX3CR1.A chemotactic receptor for the human CX3Cchemokine FKN and a fusion coreceptor for HIV-1[J], Biol Chem,1998;273(37):23799-23804.
[22]. Baggiolini M,Dewald B,Moser B.Human chemokines:Anupdate.Annu Rev Immunol.1997; 15:675-705.
[23]. Baggiolini M,Dewald B,Moser B.Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines.Adv Immunol.1994;55:97-179.
[24]. Nishiyori A,Minami M,Ohtani Y,et al.Localization of FKN and CX3-CR1 mRNAs in rat brain:doesFKN play a role in signaling from neuron to microglia.FEBS Lett.1998;429(2):167-172.
[25]. Mizoue LS,Bazan JF,Johnson EC,et al.Solution structure and dynamics of the CX3C chemokine domian of fractalkine and its interaction with an N-terminal fragment of CX3CR1.[J]. Biochemistry,1999,38(5):1402-1410.
[26]. Jung S. Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, et al, Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion andgreen fluorescent protein reporter gene insertion.Mol Cell Biol.2000; 20(11):4106—4114.
[27]. Nishimura M, Umehara E Nakayama T, et al. Dual funaioas of fractalkine/CX3CRⅠ in trafficking of circulating cytomxie effector lymphocytcs that are defined by CX3CR1 expression. [J] Immunol.2002;138:6173-6180.
[28]. Frafieelli P, Sironi M, Bianchi Get al. Fmetalkine(CX3CLI)as an amplification circuit of polarized Thl responses. [J] Clin Invest.2001;107:1173-1181.
[29]. Haskell CA, Hancock WW, Salant DJ, Gao W, Csizmadia V, Peters W, et al. Targeted deletion of CX(3)CRI reveals a role for fractalkine in cardiac allograft rejection. [J] Clin Invest.2001; 108(5):679-688。
[30]. Faure S,Meyer L,Costagliola D,et al.Rapid progression to ADIS among HIV-1 individuals with an allelic variant of CX3CR1 chemokine receptor. [J].science,2000,287:2274-2277.
[31]. Umehara H,Goda S,Imai T,et al.FKN.a CX3C-chemokine functions predominantlyas an adhesion molecule in monocytic cell line THP-1.Immunol Cell Biol.2001,79:298-3021.
[32]. Umehara H, Bollm ET, Okazaki T,et al.Fractalkine and vascular injury. [J] Trends Immunol,2001,22:602-607.
[33]. Kerfoot SM, Lord SE,Bell RB,et al.Human fractalkine mediates leukocyte adhesion but not capture under physiological shear conditions:a mechanism for selective monocyte recruitment.[J] Eur J Immunol,2003,33:729-739
[34].34 Ancuta P,Rao R,Moses A,et all Fkn preferentially mediates arrest and migration of CD 16+monocytes. [J] Exp Med.2003; 197:1701-17071.
[35]. Foussat A, Coulomb-L'Hermine A, Gosling J, Krzysiek R, Durand-Gasselin I, Schall T, et al. Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production offractalkine in human. Eur J Immunol.2000; 30(1):87-97.
[36]. Harcourt J,Alvarez R,Jones LP,et al.Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1 T+cell respones. [J].Immunol.2006,176:1600-1608
[37]. Yoneda O,Imai T,Gouda S,et al.NK cell-mediated vascularinjury.[J].Immunol 2000; 164:4055-4621.
[38]. Yoneda O,Imai T,Inoue H,et al.Membrane bound form of FKN induces IFN-r production by NK cells:a role for Thl response.Eur J Immunol.2003;33:53-581.
[39]. Nishimura M,Umehara H,Nakayama T,et al.Dual functions of Fkn/CX3CR1 intrafficking of circulating cytotoxic effector lymphocytes that are defined by CX3CR1 expression.[J] Immunol.2002;138:6173-61801.
[40]. Ross R,Atherosclerosis is an inflammatory disease.Am Heart [J].1999,138 (5pt2): S419-420.
[41]. Poole JC,Florey HW.Changes in the endothelium of the aorta and the behavior Of macrophages in experimental atheroma of rabbits.[J]Pathol Bacteriol.1958;75:245-251.
[42]. Steinberg D.Atherogenesis in PersPeetive:hypercholesterolemia and inflamm-ation as Partuers in crime.NatMed.2002;8:1211-1217.
[43]. Sheikine Y,Hansson G.Chemokines and atheroselerosis.Ann Med.2004;36:98-118.
[44]. Yla Herttuala S,Lipton BA.Rosenfeld ME,et al.Expression of monoeyte chemo-attractant protein-1 in macrophage-rich areas of human and rabbit atherosclerotic lesions,Proc Natl Acid USA.1991;88:5252-5256.
[45]. Yu X,Dluz S,Graves DT,et al.Elevated expression of monocyte chemo-attractant Proteinl by vascular smooth muscle cells in hypercholesterolemic Primates.Proc Natl Acid Sci USA.1992;89:6953-6957.
[46]. Reape TJ,Rayner k,Manning CD,et al.Expression and cellular localization of the CC ehemokines PARC and ELC in human atheroselerotic Plaques.Am J Pathol.1999; 154:365-74.
[47]. Greaves DR,Hakkinen T,Lucas AD,et al.Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, thymus and activation-regulated chemokine are expressed in human atherosclerotic lesions.Arterioscler Thromb Vasc Biol.2002;21:923-929.
[48]. Haque N, Zhang X, French D, et al.CC ehemokine 1-309 is the Principal mono-Cyte chemoattractant induced by apolipoprotein in huaman vacular endothelial cell. [J] Circulation.2000;102:786-792.
[49]. Pattison JM, Nelson PJ, Huie P, et al.Rantes chemokine expression in transpla-Lant-associated aceelerated atherosclerosis.J Heart Lung Transplant.1966;15:1194-1199.
[50]. GuPta SK,et al.J Biol Chem.1998;273:4282-4287.
[51]. Hayes IM,et al.Arterioseler Thromb Vasc Biol.1998:18:397-403.
[52]. Combadiere C, Potteaux S, Gao JL, et al.DeCreased atherosClerotic lesionFonnation in CXCRI/apolipoprotein E double knockout mice. [J]Circulation.2003; 107:1009-1016.
[53]. Mallat Z, Corbaz A, Scoazec A,et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. [J] Circulation,2001,104:1598-1603
[54]. Blankenberg S,Luc G,Ducimetiere P,et al.Interleukin-18 and the risk of coronary heart disease in European men: the prospective epidemiological study of myocardial Infarction (PRIME).[J] Circulation,2003,108(9):2453
[55]. Matsubara T, Ono T, Yamanoi A, et al. Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma[.J] SUR ONC.2007;95(3):241-249.
[56]. L Tang, et al. Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress efectively mouse hepatocellular carcinoma. Gone Ther.2007,14(4):1226-1234
[57]. Zhang XJ, Wei HM, Chen QF, et al, Activation of human natural killer cells bv recombinant membrane-expressed fraetalkine on the surface of tumor cells.Oncology Reports.2007;17(6):1371-1375.
[58]. Ohta M, Tanaka F, Yamaguchi H, et al. lfhe high expression of fraetalkine results in a better prognosis for colorectal cancer patients. Int J Oncol.2005;6(21):41-47
[59]. Robinson LA,Nataraj C, Thomas DW,et al. A role for fractalkine and its receptor (CX3CR1) in cardiac allograf rejection. [J] Immunol.2000;165:6067-6072.
[60]. Pictrzyk MC, Banas B, Wolf K, et al. Quantitative gene expression analysis of fractalkine using laser microdisseetion in biopsies from kidney allografis with acute rejection. Transplant Proc.2004; 36(9):2659-2661.
[61]. Cao G,Lu Y, Gao R, et a 1.Expression of fractalkine, CX3CRI, and vascular endothelial growth factor in human chronic renal allograft rejection. Transplant Proe.2006; 38(7): 1998-2000.
[62]. Hskell C, Hancock WW,Salant DJ, et al. Targeted deletion ofCX3CRI reveals a role for fractalkine in cardiac allograf rejection. [J] Clinlnvest.2001;108:679-688.
[63]. Feng L, Chen S, Gareia GE, et al. Prevention of ciescentie glomemlonephritis by irrmanoneutralization of the fractalkine receptor CX3CR1 rapid communication. Kidney Int.1999;56(2):612-620.
[64]. Cockwell P, Chakravorty SJ, Girdlestone J,et al.Fractalkine expression in human renal inflammation.[J] Pathol.2002;196(1):85-90.
[65]. Combadiere B, Faure S, Autran B, et al. The chemokine receptor CX3CR1 controls homing and anti-viral potencies of CD8 effeetor-mcmory T lymphoeytes in HW-infeeted patients.AIDS.2003;17(9):1279-1290.
[66]. Foussat A, Bouchet-Delbos L, Berrebi D, et al. Deregulation ofthe expression of the fraetalkine/flacctalkine receptor complex in HIV-1·infected patients. Blood.2001;98(6): 1678-1686.
[67]. Faure S,Meyer L,Costagliola D,et al.Rapid progression to AIDS in HIV+individuals with a structural variant of the chemokine receptor CX3CR1.[J] Science,2000,287:2274-2277.
[68]. Marasini B,Cossutta R,Selmi C,et al.Polymorphism of fractalkine receptor CX3CR1 and systemic sclerosis-associated pulmonary arterial hypertension.Clin Dev Immunol,2005, 12:275-279.